Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
38 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Anaphylaxis - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anaphylaxis - Pipeline Review, H2 2016, provides an overview of the Anaphylaxis (Immunology) pipeline landscape. Anaphylaxis is a severe, potentially life-threatening allergic reaction. Anaphylaxis symptoms include dizziness, nausea, vomiting or diarrhea, feeling of warmth, constriction of the airways and a swollen tongue or throat. Risk factors include personal history of anaphylaxis, allergies or asthma and family history. Treatment includes beta-agonist, antihistamines and cortisone. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anaphylaxis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Anaphylaxis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Anaphylaxis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Anaphylaxis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn and Preclinical stages are 1 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.Anaphylaxis. Anaphylaxis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Anaphylaxis (Immunology). - The pipeline guide reviews pipeline therapeutics for Anaphylaxis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Anaphylaxis (Immunology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Anaphylaxis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Anaphylaxis (Immunology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Anaphylaxis (Immunology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Anaphylaxis (Immunology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Anaphylaxis Overview 6 Therapeutics Development 7 Pipeline Products for Anaphylaxis - Overview 7 Pipeline Products for Anaphylaxis - Comparative Analysis 8 Anaphylaxis - Therapeutics under Development by Companies 9 Anaphylaxis - Therapeutics under Investigation by Universities/Institutes 10 Anaphylaxis - Pipeline Products Glance 11 Late Stage Products 11 Early Stage Products 12 Anaphylaxis - Products under Development by Companies 13 Anaphylaxis - Products under Investigation by Universities/Institutes 14 Anaphylaxis - Companies Involved in Therapeutics Development 15 Adamis Pharmaceuticals Corp 15 MannKind Corp 16 Monosol Rx LLC 17 Anaphylaxis - Therapeutics Assessment 18 Assessment by Monotherapy Products 18 Assessment by Target 19 Assessment by Mechanism of Action 21 Assessment by Route of Administration 23 Assessment by Molecule Type 25 Drug Profiles 27 epinephrine - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 epinephrine - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 epinephrine - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 epinephrine - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 ET-523 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 Monoclonal Antibody to Antagonize FcgR1 for Inflammatory and Autoimmune Disorders - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 Monoclonal Antibody to Antagonize FcgRIIa for Inflammatory and Autoimmune Disorders - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 Anaphylaxis - Dormant Projects 35 Anaphylaxis - Product Development Milestones 36 Featured News & Press Releases 36 Sep 10, 2013: Novel Nasal Epinephrine Shows Comparable Absorption to EpiPen(R) in a Feasibility Study 36 Appendix 37 Methodology 37 Coverage 37 Secondary Research 37 Primary Research 37 Expert Panel Validation 37 Contact Us 37 Disclaimer 38
List of Tables
Number of Products under Development for Anaphylaxis, H2 2016 7 Number of Products under Development for Anaphylaxis - Comparative Analysis, H2 2016 8 Number of Products under Development by Companies, H2 2016 9 Number of Products under Investigation by Universities/Institutes, H2 2016 10 Comparative Analysis by Late Stage Development, H2 2016 11 Comparative Analysis by Early Stage Development, H2 2016 12 Products under Development by Companies, H2 2016 13 Products under Investigation by Universities/Institutes, H2 2016 14 Anaphylaxis - Pipeline by Adamis Pharmaceuticals Corp, H2 2016 15 Anaphylaxis - Pipeline by MannKind Corp, H2 2016 16 Anaphylaxis - Pipeline by Monosol Rx LLC, H2 2016 17 Assessment by Monotherapy Products, H2 2016 18 Number of Products by Stage and Target, H2 2016 20 Number of Products by Stage and Mechanism of Action, H2 2016 22 Number of Products by Stage and Route of Administration, H2 2016 24 Number of Products by Stage and Molecule Type, H2 2016 26 Anaphylaxis - Dormant Projects, H2 2016 35
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.